Extract
Mepolizumab and benralizumab are monoclonal antibodies (mAbs) approved for the treatment of severe eosinophilic asthma (SEA), targeting interleukin (IL)-5 and IL-5R, respectively [1]. In appropriately selected patients, their use leads to significant reductions in asthma exacerbations and maintenance oral corticosteroid (mOCS) dose [2, 3].
Abstract
In a real-world setting, the clinical response to the anti-IL-5/5R mAbs mepolizumab and benralizumab in patients with severe eosinophilic asthma is independent of co-eligibility with the anti-IgE mAb omalizumab https://bit.ly/2NfAitP
Footnotes
Conflict of interest: A.P. Hearn has nothing to disclose.
Conflict of interest: O.D. Hug has nothing to disclose.
Conflict of interest: Z.A. Somani has nothing to disclose.
Conflict of interest: J. Kavanagh reports other (travel support for meetings) from Teva, outside the submitted work.
Conflict of interest: G. d'Ancona reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work.
Conflict of interest: C. Roxas has nothing to disclose.
Conflict of interest: L. Green has nothing to disclose.
Conflict of interest: L. Thomson has nothing to disclose.
Conflict of interest: M. Fernandes has nothing to disclose.
Conflict of interest: B.D. Kent reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work.
Conflict of interest: J. Dhariwal reports other (travel support for meetings) from Sanofi, outside the submitted work.
Conflict of interest: A.M. Nanzer reports other (travel support for meetings) from Napp, and personal fees for lectures from AstraZeneca, outside the submitted work.
Conflict of interest: D.J. Jackson reports personal fees for lectures from Teva, GSK, AstraZeneca, Chiesi and Napp, outside the submitted work.
- Received December 16, 2020.
- Accepted February 4, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org